Disease-Modifying Antirheumatic Drugs
Key Points
- DMARDs differ from NSAIDs and corticosteroids by modifying the course of autoimmune disease, not just managing symptoms — they slow joint destruction and prevent disability.
- Methotrexate is the gold-standard conventional DMARD for rheumatoid arthritis (RA).
- All DMARDs cause immunosuppression — infection risk is elevated; monitor CBC, LFTs, and renal function regularly.
- Methotrexate is teratogenic — pregnancy must be avoided; folic acid supplementation is required to reduce side effects.
- DMARDs take weeks to months for therapeutic effect — bridging therapy with corticosteroids is often used initially.
Pathophysiology Context
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by synovial inflammation, cartilage degradation, and progressive joint destruction. Autoantibodies (rheumatoid factor, anti-CCP) trigger an inflammatory cascade involving T cells, B cells, macrophages, and cytokines (TNF-α, IL-1, IL-6).
DMARDs target these autoimmune processes to preserve joint architecture. Without DMARD therapy, irreversible joint deformity and functional loss progress over years.
Classification of Conventional DMARDs
| Drug | Mechanism | Primary Use | Key Consideration |
|---|---|---|---|
| Methotrexate | Anti-folate → inhibits T cell and B cell proliferation | RA first-line DMARD | Weekly dosing; folic acid supplement required; hepatotoxic |
| Hydroxychloroquine (Plaquenil) | Antimalarial; modulates lysosomal pH; reduces cytokine activity | Mild RA; lupus (SLE) | Retinal toxicity → ophthalmology exams every 1–2 years |
| Sulfasalazine | Anti-inflammatory; reduces immune activation | RA, inflammatory bowel disease | GI side effects common; sulfa allergy contraindication |
| Leflunomide (Arava) | Inhibits pyrimidine synthesis → suppresses T cell proliferation | RA (alternative to methotrexate) | Hepatotoxic; teratogenic; long half-life (active metabolite persists months) |
| Azathioprine (Imuran) | Inhibits DNA synthesis; suppresses T and B cell proliferation | RA, SLE, organ transplant | CBC monitoring for bone marrow suppression; TPMT genetic deficiency = toxicity risk |
Nursing Assessment
NCLEX Focus
The highest-priority monitoring concern for DMARDs is infection risk from immunosuppression. A patient on methotrexate or leflunomide with fever, cough, or mouth sores requires prompt assessment — these findings may indicate a serious opportunistic infection.
- Assess baseline CBC, LFTs, serum creatinine before initiating DMARD therapy.
- Assess for active infection — DMARDs are contraindicated with active serious infections.
- Assess pregnancy status — multiple DMARDs are teratogenic (methotrexate, leflunomide).
- Assess for sulfa allergy before sulfasalazine administration.
- Assess joint status: ROM, morning stiffness duration, swelling, pain level.
- Screen for latent tuberculosis before initiating biologic DMARDs (see biologic-response-modifiers).
Nursing Interventions
- Monitor CBC regularly: Methotrexate and azathioprine cause bone marrow suppression (leukopenia, thrombocytopenia, anemia).
- Monitor liver function tests (LFTs): Methotrexate and leflunomide are hepatotoxic; avoid alcohol completely with methotrexate.
- Folic acid supplementation: Administer with methotrexate to reduce mucosal and hematologic toxicity (1 mg daily or 5 mg weekly).
- Infection surveillance: Report fever, signs of infection promptly — hold DMARD and notify provider.
- Contraception counseling: Emphasize effective contraception during DMARD therapy; advise 3-month washout for methotrexate and longer washout for leflunomide before conception.
- Ophthalmology referral: Arrange baseline and annual eye exams for patients on hydroxychloroquine.
- Patient education on delayed onset: DMARDs require 1–3 months for full effect; adherence is essential; do not discontinue abruptly.
- Live vaccines: Avoid live vaccines during DMARD therapy (immunosuppression increases risk of vaccine-associated infection).
- Severe-cutaneous/systemic reaction watch: Escalate rash, mucosal injury, fever, arrhythmia symptoms, jaundice, or unusual bleeding immediately because rare but life-threatening events (for example DRESS, SJS/TEN, hepatotoxicity, aplastic-anemia patterns) can occur.
Methotrexate Hepatotoxicity and Teratogenicity
Methotrexate is both hepatotoxic and teratogenic. Teach patients to: (1) avoid alcohol completely; (2) use effective contraception; (3) report any unusual bruising, mouth sores, or shortness of breath. LFTs and CBC must be monitored at regular intervals (typically every 4–8 weeks).
Pharmacology
| Drug | Monitoring | Safety Alerts |
|---|---|---|
| Methotrexate | CBC, LFTs, renal function every 4–8 weeks | Weekly dosing (NOT daily); folic acid required; teratogenic |
| Hydroxychloroquine | Ophthalmology every 1–2 years | Lower toxicity profile vs. other DMARDs; useful in pregnancy-compatible scenarios |
| Sulfasalazine | CBC, LFTs | GI side effects (nausea) — take with food; sulfa allergy = contraindication |
| Leflunomide | CBC, LFTs | Teratogenic; cholestyramine washout if pregnancy desired |
| Azathioprine | CBC; TPMT genotype | Myelosuppression risk; black box warning for malignancy |
Clinical Judgment Application
Clinical Scenario
A patient with RA has been on weekly methotrexate for 3 months. At a clinic visit, their CBC shows WBC 2,800 cells/µL and ALT 95 U/L (normal ≤40). The patient mentions drinking wine 2–3 nights per week.
- Recognize Cues: Leukopenia and elevated LFTs in a patient on methotrexate who drinks alcohol.
- Analyze Cues: Methotrexate hepatotoxicity is likely worsened by alcohol; bone marrow suppression is present.
- Prioritize Hypotheses: Hepatotoxicity and infection risk from leukopenia are priority concerns.
- Generate Solutions: Hold methotrexate; notify provider; counsel on alcohol abstinence; order repeat labs.
- Take Action: Document abnormal lab values; withhold next dose; educate patient on alcohol prohibition.
- Evaluate Outcomes: LFTs normalize and WBC returns to normal range after dose adjustment and alcohol cessation.
Related Concepts
- biologic-response-modifiers — Biologic DMARDs (TNF inhibitors, IL-6 inhibitors) are used when conventional DMARDs fail.
- rheumatoid-arthritis-autoimmune-joint-disease — RA as the primary indication for DMARD therapy.
- inflammatory-bowel-disease — Azathioprine and sulfasalazine are also used in IBD management.
- corticosteroids — Used as bridging therapy while DMARDs reach therapeutic levels.
- nsaids — NSAIDs provide symptom relief but do not alter disease progression.
Self-Check
- How does the mechanism of DMARDs differ from NSAIDs in treating rheumatoid arthritis?
- Why must folic acid be co-administered with methotrexate?
- What eye-related monitoring is required for patients taking hydroxychloroquine?